What is the appropriate management for a patient who started immediate‑release amphetamine‑dextroamphetamine (Adderall) 5 mg a few weeks ago and reports that the effect wears off after about 4 hours?

Management of Short-Duration Immediate-Release Amphetamine-Dextroamphetamine

Increase the dose of immediate-release amphetamine-dextroamphetamine or add a second dose 4-6 hours after the first dose, as the 4-hour duration is expected for this formulation and requires either dose optimization or multiple daily dosing.

Understanding the Problem

The patient is experiencing the expected pharmacokinetic profile of immediate-release (IR) Adderall. This is not treatment failure—it's how IR formulations work. According to the FDA label, IR amphetamine-dextroamphetamine has a duration of action of approximately 4-6 hours, and the prescribing information explicitly states to "give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours" 1.

Algorithmic Approach to Management

Step 1: Optimize IR Dosing First

• Increase the current 5 mg dose in 5 mg increments at weekly intervals until optimal response is obtained (for patients ≥6 years old) 1
• Add a second (or third) dose spaced 4-6 hours apart from the first dose 1
• The FDA label permits up to 40 mg total daily dose, though this is rarely necessary 1

Rationale: Before switching formulations, ensure the current medication is being used correctly. Many patients on IR formulations require 2-3 doses daily to maintain coverage throughout the day.

Step 2: If Multiple Daily Dosing is Impractical, Switch to Extended-Release

If the patient cannot reliably take multiple doses or prefers once-daily dosing:

• Switch to an extended-release amphetamine formulation such as:
  • Mixed amphetamine salts extended-release (MAS XR/Adderall XR): provides 12-hour coverage with rapid onset within 1.5 hours 2
  • Lisdexamfetamine (Vyvanse): provides "around-the-clock" effects 3
  • Dyanavel XR: associated with reduced need for IR supplementation compared to other ER formulations 4

Conversion: When switching from IR to ER, use the same total daily dose. For example, if optimized on 10 mg IR twice daily (20 mg total), start MAS XR 20 mg once daily 2.

Step 3: Monitor for Adequate Coverage

After optimization, assess:

• Symptom control throughout the day: morning, afternoon, and evening
• Functional impairment: work/school performance, social functioning
• Adverse effects: appetite suppression, insomnia, cardiovascular effects (blood pressure, heart rate) 1, 5

Critical Considerations

Why IR Formulations Wear Off Quickly

IR amphetamines have a rapid onset (within 1.5 hours) but short duration (4-6 hours) 6, 2. This is pharmacologically expected and not a sign of treatment resistance or inadequate dosing per se.

Extended-Release Advantages

ER formulations provide:

• 12-hour symptom coverage with once-daily dosing 2
• Reduced rebound symptoms when medication wears off 3
• Improved adherence by eliminating midday dosing 3
• Similar efficacy to multiple IR doses but with convenience 2

Research shows that dextroamphetamine Spansules (an older ER formulation) demonstrated "more sustained effects" lasting 3-6 hours longer than IR formulations, though with slightly less robust morning effects 6.

Avoid Common Pitfalls

1. Don't assume treatment failure: A 4-hour duration is normal for IR formulations
2. Don't underdose: The starting 5 mg dose is often subtherapeutic and requires titration 1
3. Don't ignore late-day coverage needs: Many patients need symptom control into the evening for homework, driving, or social activities
4. Monitor cardiovascular effects: Amphetamines increase systolic BP by ~2 mmHg, diastolic BP by ~2 mmHg, and heart rate by ~4 bpm 5—monitor blood pressure and pulse at each visit 1

Timing of Doses

• First dose: Upon awakening 1
• Subsequent doses: 4-6 hours after the previous dose 1
• Avoid late evening doses: Can cause insomnia 1

Evidence Quality Note

The FDA drug label 1 provides the highest-quality guidance for dosing schedules and is consistent with clinical practice guidelines 3 that recommend stimulants as first-line therapy with individualized dosing based on symptom response. The evidence supporting ER formulations for improved duration of action is robust, with multiple studies demonstrating 12-hour coverage 2 and reduced need for supplementation 4.